WHO COVID-19 dashboard
WHO Health Emergencies Programme
The objective of this report is to provide a comprehensive overview of reported data on SARS-CoV-2 viral activity and the burden of the COVID-19 on the human population over the past seven to 28 days from the last reporting date. This overview and other sections are based on data submitted by Member States' Ministries of Health to the World Health Organization (WHO) through various surveillance systems, as well as updates from the health ministries' websites of the Member States. Information in this overview should be interpreted considering the data limitations detailed beneath each section.
Global data for COVID-19 circulation
Circulation
SARS-CoV-2 activity: Last 7 days
In the week of 1 to 7 September 2025, a total of 48,737 samples were tested for SARS-CoV-2, the virus that causes COVID-19, across 72 countries. WHO collects this data from a global network of sentinel and systematic virologic surveillance sites. Out of these, 3,149 (6.5%) samples tested positive for the virus (Table 1.1). During this period, SARS-CoV-2 activity was stable globally, with variations observed across some WHO regions (Table 1.3). Elevated activity or increases were reported in several countries in Central America and Caribbean and Tropical South America; South West, Northern, and Eastern Europe; and Western and Eastern Asia.
Country level details are available in | Circulation section
Countries with available wastewater surveillance can be found in | Wastewater section
Table 1.1 SARS-CoV-2 test positivity as reported from systematically conducted virological surveillance by WHO Region
Table 1.2 Number of countries reporting SARS-CoV-2 test positivity from systematically conducted virological surveillance by WHO Region
Table 1.3 Change in SARS-CoV-2 test positivity as reported from systematically conducted virological surveillance by WHO Region during last 52 weeks
SARS-CoV-2 reported cases: Last 28 days
In the 28-day period from 11 August 2025 to 07 September 2025, 69 countries across five WHO regions reported new COVID-19 cases. During this 28-day period, a total of 114,882 new cases were reported, which is an increase compared to the 67,130 new cases reported from 94 countries in the previous 28-day period (Table 2). Overall, 34 countries from the Americas and Europe showed an increase in new cases of over 10%.
Country level details are available in | Cases section
Table 2.1. Newly reported COVID-19 confirmed cases by WHO regions
28-days to the dateTable 2.2. Number of countries reported newly COVID-19 confirmed cases by WHO regions
28-days to the date
SARS-CoV-2 variant circulation: 3 August to 31 August 2025
WHO is currently tracking several SARS-CoV-2 variants:
- Variants of Interest: JN.1
- Variants Under Monitoring: XFG, NB.1.8.1, LP.8.1, KP.3.1.1, and XEC
The most prevalent variant, XFG, accounted for 67% of all submitted sequences in the week ending on 31 August 2025 which is an increase from 58% in the week ending on 3 August 2025. NB.1.8.1 accounted for 21% of all submitted sequences in the week ending on 31 August 2025, a decrease from 25% in the week ending on 3 August 2025 (Table 3).
During this reporting period, all other variants showed a decreasing or stable trend. Available evidence suggests that XFG and NB.1.8.1 do not pose additional public health risks relative to other currently circulating SARS-CoV-2 variants.
At the regional level, within the reporting period from week ending 03 to 31 August 2025, XFG increased in the Americas and the European Region, which were the regions with sufficient data while NB.1.8.1 decreased in the Western Pacific Region and remained stable in the European Region and the Americas.
Country level details are available in | Circulation section
Information on WHO variant monitoring is available in | Variant section
Table 3. Weekly prevalence of SARS-CoV-2 VOIs and VUMs
Updates and news
Regional Office Reports
Severity
Hospitalizations and ICU admissions: Last 28 days
In the 28-day period from 11 August 2025 to 07 September 2025, a total of 10,964 new COVID-19 hospitalizations were reported from 33 countries, and 374 new ICU admissions were reported from 29 countries across four WHO regions (Table 4 and 5). Among the 29 countries that consistently reported hospitalizations during the past and previous 28-day periods, fifteen countries from the Americas and Europe showed an increasing trend. Among the 21 countries that consistently reported ICU admissions during the past and previous 28-day periods, five countries from the Americas and Europe showed an increasing trend.
Table 4.1. Number of new hospitalization admissions reported by WHO regions
28-days to the dateTable 4.2. Number of countries reported new hospitalization admissions by WHO regions
28-days to the dateTable 4.3. Number of new ICU admissions reported by WHO regions
28-days to the dateTable 4.4. Number of countries reported new ICU admissions by WHO regions
28-days to the date
Deaths: Last 28 days
In the 28-day period from 11 August 2025 to 07 September 2025, 35 countries across four WHO regions reported new COVID-19 deaths. During this 28-day period, a total of 1,494 new deaths were reported, which is an increase compared to the 1,075 new deaths reported from 43 countries in the previous 28-day period (Table 2). Eleven countries from the Americas, Europe, and South-East Asia showed an increase in new deaths of over 10%. In August 2025, 89% of reported deaths with age information occurred in the population aged 65 and over.
Table 5.1. Newly reported COVID-19 confirmed deaths by WHO regions
28-days to the dateTable 5.2. Number of countries reported newly COVID-19 confirmed deaths by WHO regions
28-days to the date
Additional Information
Vaccination
Quarterly time series data on COVID-19 vaccine uptake and the target population groups recommended for vaccination under national COVID-19 vaccination policies are available by country through Quarter 4 of 2024 in the Data Section.
Metadata
Glossary
| SARS-CoV-2 PCR percent positivity | The data presented in this section shows the volume of testing, the number of detections, and the percent positivity for SARS-CoV-2 over time from sentinel surveillance and other types of systematically conducted virologic surveillance. Percent positivity is calculated using the reported number of samples positive and processed for SARS-CoV-2. Number of processed samples is either provided by countries or calculated from the number of positive and negative samples. |
| COVID-19 variants | It is usual for viruses to change and evolve as they spread between people over time. When these changes become significantly different from a previously detected virus, these new virus types are known as “variants.” Scientists map the genetic material of viruses (sequencing) to identify differences and detect changes. |
| Variant under Monitoring (VUM) | A term used to signal to public health authorities that a SARS-CoV-2 variant may require prioritized attention and monitoring. The main objective is to investigate if this variant may pose an additional threat to global public health. |
| Variant of Interest (VOI) | A SARS-CoV-2 variant with changes affecting its behavior or potential impact on human health, such as its ability to spread, cause serious disease, or respond to treatment. A VOI may also have an increased ability to spread, suggesting an emerging risk to global public health. |
| Wastewater | Water that has been in contact with people (e.g., for washing) or used for cleansing and sanitation (e.g., for flushing away faecal matter), and is discharged via sewers or other sanitation systems. |
| Wastewater surveillance | Sampling and testing of wastewater to analyze and interpret results, including assessing the presence or concentration of pathogens and substances, aimed at enhancing our understanding of disease dynamics within a community. |
| Environmental Surveillance | Systematic monitoring and assessment of various aspects of the environment, including air, water, soil, and biodiversity. |
Definitions
| SARS-CoV-2 PCR percent positivity | Data on respiratory virus surveillance are provided to WHO through participation or collaboration with the Global Influenza Surveillance and Response System (GISRS). Countries, areas, and territories use a variety of approaches to monitor respiratory virus activity, and data in this report may vary from surveillance reports posted elsewhere. Data in this dashboard include virologic results from sentinel surveillance and other types of systematically conducted virologic surveillance, depending on the countries, areas, and territories. Differences in surveillance approaches limit comparison of percent positivity between countries, areas, and territories. The source to use in the dashboardwas determined in collaboration with WHO Regional Offices and the reporting countries, areas, and territories. Analyses stratified by source of surveillance is available through the GISRS surveillance data dashboard alongside influenza circulation. The data presented in this section shows the volume of testing, the number of detections, and the percent positivity for SARS-CoV-2 over time. Data is excluded whenever only the number of SARS-CoV-2 positives or negatives is reported without the denominator (number of samples tested). Currently, there are a limited number of countries reporting this data to GISRS in a timely and consistent way. When world or a WHO Region is selected, the data reported to date might be from a limited number of countries, and thus the trends in percent positivity do not reflect the situation as a whole in the region or globally. The quality and consistency of current data are influenced by changes in health-seeking behaviors, routines in sentinel sites, national testing priorities, and capacities. The data is subject to change over time if there is retrospective and delayed reporting or updating of previously reported data. Global Influenza Program influenza updates can be found here. |
| SARS-CoV-2 variant data | Data on variants are provided through GISAID. |
Copyright and licensing
| Copyright | Attribution 4.0 International (CC BY 4.0) |
|---|---|
| License | The World Health Organization (“WHO”) encourages public access and use of the data that it collects and publishes on its web site data.who.int. The data are organized in datasets and made available in machine-readable format (“Datasets”). The Datasets have been compiled from data provided by WHO’s Member States under the WHO policy on the use and sharing of data collected by WHO in Member States outside the context of public health emergencies. Use of the data derived from the Datasets, which may appear in formats such as tables and charts, is also subject to these Terms and Conditions. Datasets may include data describing the Dataset called “Metadata”. If any datasets are credited to a source other than WHO, then those materials are not covered by these Terms and Conditions, and permission should be sought from the source provided. You are responsible for determining if this is the case, and if so, you are responsible for obtaining any necessary permission from the sources indicated. The risk of claims resulting from infringement of any third-party-owned component in the materials rests solely with you. You may use our application programming interfaces (“APIs”) to facilitate access to the Datasets, whether through a separate web site or through another type of software application. By using the Datasets or any presentations of data derived from them, or by using our APIs in connection with the Datasets, you agree to be bound by these Terms and Conditions, as may be amended from time to time by WHO at its sole discretion. Unless specifically indicated otherwise, these Datasets are provided to you under a Creative Commons Attribution 4.0 International License (CC BY 4.0), with the additional terms below. The basic terms applicable to the CC BY 4.0 license may be accessed here. By downloading or using the Datasets, you agree to comply with the terms of the CC BY 4.0 license, as well as the following mandatory and binding addition: Any dispute relating to the interpretation or application of this license shall, unless amicably settled, be subject to conciliation. In the event of failure of the latter, the dispute shall be settled by arbitration. The arbitration shall be conducted in accordance with the modalities to be agreed upon by the parties or, in the absence of agreement, with the UNCITRAL Arbitration Rules. The parties shall accept the arbitral award as final. |
| Permission type | Publicly accessible |
| Prohibited uses | You shall not attempt to de-anonymise the Datasets or use the Datasets in a manner that falsifies or misrepresents their content. You shall not, in connection with your use of the Datasets published on data.who.int, state or imply that WHO endorses, or is affiliated with, you, or that WHO endorses your use of data.who.int, or any content, output, or analysis resulting from or related to the data.who.int, or any entity, organization, company, product or services. |
| Citation | World Health Organization 2023 data.who.int, WHO Coronavirus (COVID-19) dashboard > More resources [Dashboard]. https://data.who.int/dashboards/covid19/more-resources |
| Disclaimer | WHO reserves the right at any time and from time to time to modify or discontinue, temporarily or permanently, the Datasets, or any means of accessing or utilizing the Datasets with or without prior notice to you. Maps All references to Kosovo should be understood to be in the context of the United Nations Security Council resolution 1244 (1999). A dispute exists between the Governments of Argentina and the United Kingdom of Great Britain and Northern Ireland concerning sovereignty over the Falkland Islands (Malvinas). The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the accuracy of the Datasets. However, the Datasets are being provided without warranty of any kind, either expressed or implied. You will be solely responsible for your use of the Datasets. In no event shall WHO be liable for any damages arising from such use. Regional reclassification for Indonesia: 1 January 2025, Indonesia has been reclassified from the WHO South-East Asia Region to the Western Pacific Region. As a result, data to and including 31 December 2024 will be reported under the South-East Asia Region, while data from 1 January 2025 onward will be reported under the Western Pacific Region for this country up. For full disclaimers, terms of use and your indemnification of WHO, please visit Terms and Conditions. |